Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut Paoli-Calmettes
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients diagnosed with Multiple Myeloma who were eligible for high-dose melphalan supported with autologous hematopoietic stem cell transplantation (HSCT) as part of their treatment plan
First mobilization attempt
"rhG-CSF alone" mobilization regimen
Failed mobilization as documented by an increase in CD34+ cell mobilization deemed insufficient to initiate apheresis (below 15/µL), after the 4 first injections of rhG-CSF that are administered in the evening
You may not be if
Age \< 18 years;
Primary diagnosis other than MM
2nd or subsequent mobilization attempt
Patients who previously received HDCT + autologous HSCT
Chemotherapy-based mobilization regimen
Efficient mobilization, allowing for apheresis and collection of the target cell number (5x106 CD34+ cells/kg for every planned autologous transplantation as per institutional SOPs).
